Combination therapy with polymyxin B for carbapenemase-producing Klebsiella pneumoniae bloodstream infection

Klebsiella pneumoniae isolates are among the most common bacteria causing hospital acquired infections, including bloodstream infections (BSIs) [1, 2]. Carbapenems used to be the antimicrobials of last resort against Enterobacteriaceae, including K. pneumoniae; however, the activity of this class has been threatened by the emergence of carbapenemase producing isolates, notably KPC-producing K. pneumoniae (KPC-KP) [1, 2]. Infections caused by KPC-KP usually affect patients with multiple comorbidities and are associated with higher mortality rates [3].
Source: International Journal of Antimicrobial Agents - Category: Drugs & Pharmacology Authors: Source Type: research